In February, the FDA refused to approve diabetes drug
Tresiba and its sister drug Ryzodeg without more safety data. But Novo Nordisk waited two days to reveal that info to the public--and Danish authorities aren't happy about that.
Novo Nordisk noted today that the Danish Financial Supervisory Authority informed it of its decision to call in the cops after concluding that Novo Nordisk didn't obey the letter of the law as written in Section 27 (1) of the Danish Securities...
Danish drug maker Novo Nordisk said it expects to file for U.S. regulatory approval for its new obesity drug "within weeks," in a bid to diversify a product portfolio that is focused on diabetes treatments.
OncoMed Pharmaceuticals (NASDAQ: OMED) shares moved up 71.49% to $24.01. The volume of OncoMed Pharmaceuticals shares traded was 4116% higher than normal. OncoMed shares jumped on a deal to sell 1.47 million shares to Celgene (NASDAQ: CELG) at...
Novo Nordisk, the world leader in insulin products, took a big hit this year when the FDA denied approval of its newest long-lasting insulin drug, Tresiba. But CEO Lars Rebien Sørensen is taking every opportunity to let the markets know that Novo...
Despite a major setback earlier this year when the FDA rejected Novo Nordisk's application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway.
Novo seems to believe that payors will pay a premium for a new product just because it is new, when in reality payors are recognizing what everyone else has, in that these so-called new drugs don't offer a compelling case for premium reimbursement.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):